No Data
InflaRx Spotlights Izicopan HS Data, Phase 2b Plans and 30% Cost Cuts at Guggenheim Summit
Biotech Showcase 2026 Brought Early-Stage Biotech Innovation to the Forefront During JPM Healthcare Week
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR), InflaRx (IFRX) and Verastem (VSTM)
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
InflaRx Announces Participation in February Investor Conferences
InflaRx Plans Workforce Reduction, Targets Mid-2027 Cash Runway